Hologic Acquires Focal Therapeutics for $125M to Strengthen its Breast Surgery Platform

 Hologic Acquires Focal Therapeutics for $125M to Strengthen its Breast Surgery Platform

Hologic Acquires Focal Therapeutics for $125M to Strengthen its Breast Surgery Platform

Shots:

  • Hologic to acquire Focal for its BioZorb marker, an implantable 3D marker helping surgeons to overcome challenges in breast conserving surgery, or lumpectomy used to mark tumor excision site
  • The acquisition on focus on treating breast cancer patients by improving Qol with 3D indicator at surgical site
  • The US FDA has already granted 510(k) clearance to BioZorb, available in a range of sizes. The transaction is expected to close in Oct 2018

Click here to read full press release/ article | Ref: Hologic | Image: Ofordglobal

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post